121 Matching Annotations
  1. Last 7 days
    1. Benjy Renton on Twitter: “Over half of those who answered ‘wait and see’ to @KFF’s vaccine poll in January have now received the vaccine. So what changed their mind? - Seeing friends and family without side effects—Doctors and healthcare providers encouraging them https://t.co/iRxWp2BLTQ https://t.co/XStHV975Qt” / Twitter. (n.d.). Retrieved August 2, 2021, from https://twitter.com/bhrenton/status/1415163661291819008?s=20

  2. Jul 2021
    1. Dr. Jeff Benyacar on Twitter: “@AlexBerenson ‘Even if a link between myocarditis and the vaccine holds up, the condition is usually mild, requiring treatment only with anti-inflammatory drugs, whereas COVID-19 infection can also cause serious disease and long-term side effects, even in young people.’ https://t.co/3VQprF7bIz” / Twitter. (n.d.). Retrieved July 2, 2021, from https://twitter.com/jbenyacar/status/1399851524487106562?s=12

    1. Adam Kucharski on Twitter: “Useful data 👇– quick look suggests odds ratio for detection of B.1.617.2 relative to non-B.1.617.2 in vaccinated group compared to controls is 2.7 (95% CI: 0.7-10) after one dose and 1.2 (0.4-3.6) after two...” / Twitter. (n.d.). Retrieved July 2, 2021, from https://twitter.com/AdamJKucharski/status/1400443351908892675?s=20

  3. Jun 2021
    1. Borobia, A. M., Carcas, A. J., Pérez-Olmeda, M., Castaño, L., Bertran, M. J., García-Pérez, J., Campins, M., Portolés, A., González-Pérez, M., García Morales, M. T., Arana-Arri, E., Aldea, M., Díez-Fuertes, F., Fuentes, I., Ascaso, A., Lora, D., Imaz-Ayo, N., Barón-Mira, L. E., Agustí, A., … Torvisco, J. M. (2021). Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet, S0140673621014203. https://doi.org/10.1016/S0140-6736(21)01420-3

    1. Regev-Yochay, G., Amit, S., Bergwerk, M., Lipsitch, M., Leshem, E., Kahn, R., Lustig, Y., Cohen, C., Doolman, R., Ziv, A., Novikov, I., Rubin, C., Gimpelevich, I., Huppert, A., Rahav, G., Afek, A., & Kreiss, Y. (2021). Decreased Infectivity Following BNT162b2 Vaccination. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3815668

    1. Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., Kuntz, J. L., Dunnigan, K., Odean, M. J., Hegmann, K. T., Stefanski, E., Edwards, L. J., Schaefer-Solle, N., Grant, L., Ellingson, K., … Gaglani, M. (2021). Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers—Eight U.S. Locations, December 2020–March 2021. MMWR. Morbidity and Mortality Weekly Report, 70(13), 495–500. https://doi.org/10.15585/mmwr.mm7013e3

    1. Parry, H. M., Tut, G., Faustini, S., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K., Amirthalingam, G., Charlton, S., Leung, S., Chiplin, E., Coombes, N. S., Bewley, K. R., Penn, E. J., Rowe, C., Otter, A., Watts, R., D’Arcangelo, S., … Moss, P. (2021). BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3816840

    1. V Shah, A. S., Gribben, C., Bishop, J., Hanlon, P., Caldwell, D., Wood, R., Reid, M., McMenamin, J., Goldberg, D., Stockton, D., Hutchinson, S., Robertson, C., McKeigue, P. M., Colhoun, H. M., & McAllister, D. A. (2021). Effect of vaccination on transmission of COVID-19: An observational study in healthcare workers and their households [Preprint]. Public and Global Health. https://doi.org/10.1101/2021.03.11.21253275

    1. Woolf, K., McManus, I. C., Martin, C. A., Nellums, L. B., Guyatt, A. L., Melbourne, C., Bryant, L., Gogoi, M., Wobi, F., Al-Oraibi, A., Hassan, O., Gupta, A., John, C., Tobin, M. D., Carr, S., Simpson, S., Gregary, B., Aujayeb, A., Zingwe, S., … Pareek, M. (2021). Ethnic differences in SARS-CoV-2 vaccine hesitancy in United Kingdom healthcare workers: Results from the UK-REACH prospective nationwide cohort study [Preprint]. Public and Global Health. https://doi.org/10.1101/2021.04.26.21255788

    1. Wall, E. C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., Hussain, S., Nicod, J., Goldstone, R., Ambrose, K., Hindmarsh, S., Beale, R., Riddell, A., Gamblin, S., Howell, M., … Bauer, D. L. (2021). Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(21)01290-3

  4. May 2021
    1. Jonathan Rothberg 🦋. (2021, March 2). Testing works. I test daily. Insist on HOME testing. @michaelmina_lab @JoeBiden Research suggests B.1.526 needs to be closely watched “for its ability to evade both monoclonal antibody and, to a certain extent, the vaccine-induced antibody,” said Fauci [Tweet]. @JMRothberg. https://twitter.com/JMRothberg/status/1366755339912306688

  5. Apr 2021
  6. Mar 2021
    1. Prof. Devi Sridhar. (2020, March 25). We will be stuck in an endless cycle of lockdown/release for next 18 months, if we do not start mass testing, tracing, & isolating those who are carriers of the virus while pursuing rapid research for antiviral treatment or vaccine. This is the message the public needs to hear. [Tweet]. @devisridhar. https://twitter.com/devisridhar/status/1242743618986745861

  7. Feb 2021
    1. Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Lambson, B. E., Vermeulen, M., Berg, K. van den, Rossouw, T., Boswell, M., Ueckermann, V., Meiring, S., Gottberg, A. von, Cohen, C., Morris, L., Bhiman, J. N., & Moore, P. L. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. BioRxiv, 2021.01.18.427166. https://doi.org/10.1101/2021.01.18.427166

  8. Jan 2021